O	0	9	Lifestyle
O	10	13	and
O	14	20	breast
O	21	27	cancer
O	28	39	recurrences
O	39	40	:
O	41	44	the
O	45	50	DIANA
O	50	51	-
O	51	52	5
O	53	58	trial
O	58	59	.

O	60	63	The
O	64	69	DIANA
O	70	71	(
O	71	75	Diet
O	76	79	and
O	80	89	Androgens
O	89	90	)
O	90	91	-
O	91	92	5
O	93	98	study
O	99	101	is
O	102	103	a
O	104	109	multi
O	109	110	-
O	110	123	institutional
O	124	134	randomized
O	135	145	controlled
O	146	151	trial
O	152	154	of
O	155	158	the
O	159	172	effectiveness
O	173	175	of
O	176	177	a
O	178	182	diet
O	183	188	based
O	189	191	on
O	192	205	Mediterranean
O	206	209	and
O	210	221	macrobiotic
O	222	229	recipes
O	230	233	and
O	234	244	principles
O	244	245	,
O	246	256	associated
O	257	261	with
O	262	270	moderate
O	271	279	physical
O	280	288	activity
O	288	289	,
O	290	292	in
O	293	301	reducing
O	302	312	additional
O	313	319	breast
O	320	326	cancer
O	327	333	events
O	334	336	in
B-eligibility	337	342	women
I-eligibility	343	347	with
I-eligibility	348	353	early
I-eligibility	354	359	stage
I-eligibility	360	368	invasive
I-eligibility	369	375	breast
I-eligibility	376	382	cancer
I-eligibility	383	385	at
I-eligibility	386	390	high
I-eligibility	391	395	risk
I-eligibility	396	398	of
I-eligibility	399	409	recurrence
I-eligibility	410	417	because
I-eligibility	418	420	of
I-eligibility	421	430	metabolic
I-eligibility	431	433	or
I-eligibility	434	443	endocrine
I-eligibility	444	450	milieu
O	450	451	.

O	452	455	The
O	456	468	intervention
O	469	471	is
O	472	480	expected
O	481	483	to
O	484	490	reduce
O	491	496	serum
O	497	504	insulin
O	505	508	and
O	509	512	sex
O	513	521	hormones
O	521	522	,
O	523	528	which
O	529	533	were
O	534	544	associated
O	545	549	with
O	550	556	breast
O	557	566	prognosis
O	567	569	in
O	570	578	previous
O	579	586	studies
O	586	587	.

O	588	595	Between
O	596	600	2008
O	601	604	and
O	605	609	2010
O	609	610	,
O	611	614	the
O	615	620	study
O	621	629	randomly
O	630	638	assigned
B-total-participants	639	643	1208
O	644	652	patients
O	653	655	to
O	656	658	an
B-intervention	659	668	intensive
I-intervention	669	673	diet
I-intervention	674	677	and
I-intervention	678	686	exercise
O	687	699	intervention
O	700	702	or
O	703	705	to
O	706	707	a
B-control	708	718	comparison
I-control	719	724	group
O	724	725	,
O	726	728	to
O	729	731	be
O	732	740	followed
O	740	741	-
O	741	743	up
O	744	751	through
O	752	756	2015
O	756	757	.

O	758	765	General
O	766	775	lifestyle
O	776	791	recommendations
O	792	795	for
O	796	799	the
O	800	810	prevention
O	811	813	of
O	814	820	cancer
O	821	824	are
O	825	830	given
O	831	833	to
O	834	838	both
O	839	845	groups
O	845	846	,
O	847	850	and
O	851	854	the
O	855	867	intervention
O	868	873	group
O	874	876	is
O	877	882	being
O	883	890	offered
O	891	892	a
O	893	906	comprehensive
O	907	916	lifestyle
O	917	929	intervention
O	929	930	,
O	931	940	including
O	941	948	cooking
O	949	956	classes
O	956	957	,
O	958	969	conferences
O	969	970	,
O	971	977	common
O	978	983	meals
O	984	987	and
O	988	996	exercise
O	997	1005	sessions
O	1005	1006	.

O	1007	1016	Adherence
O	1017	1028	assessments
O	1029	1037	occurred
O	1038	1040	at
O	1041	1049	baseline
O	1050	1053	and
O	1054	1056	at
O	1057	1059	12
O	1060	1066	months
O	1067	1070	and
O	1071	1074	are
O	1075	1082	planned
O	1083	1085	at
O	1086	1088	36
O	1089	1092	and
O	1093	1095	60
O	1096	1102	months
O	1102	1103	.

O	1104	1108	They
O	1109	1116	include
O	1117	1121	food
O	1122	1131	frequency
O	1132	1139	diaries
O	1139	1140	,
O	1141	1155	anthropometric
O	1156	1164	measures
O	1164	1165	,
O	1166	1170	body
O	1171	1174	fat
O	1175	1187	distribution
O	1188	1196	assessed
O	1197	1201	with
O	1202	1211	impedance
O	1212	1217	scale
O	1217	1218	,
O	1219	1222	one
O	1223	1227	week
O	1228	1240	registration
O	1241	1243	of
O	1244	1252	physical
O	1253	1261	activity
O	1262	1266	with
O	1267	1268	a
O	1269	1280	multisensor
O	1281	1284	arm
O	1284	1285	-
O	1285	1289	band
O	1290	1297	monitor
O	1297	1298	,
O	1299	1308	metabolic
O	1309	1312	and
O	1313	1322	endocrine
O	1323	1328	blood
O	1329	1339	parameters
O	1339	1340	.

O	1341	1348	Outcome
O	1349	1355	breast
O	1356	1362	cancer
O	1363	1369	events
O	1370	1373	are
O	1374	1382	assessed
O	1383	1390	through
O	1391	1395	self
O	1396	1402	report
O	1403	1405	at
O	1406	1410	semi
O	1411	1417	annual
O	1418	1426	meetings
O	1427	1429	or
O	1430	1439	telephone
O	1440	1449	interview
O	1450	1453	and
O	1454	1457	are
O	1458	1467	validated
O	1468	1475	through
O	1476	1483	medical
O	1484	1490	record
O	1491	1503	verification
O	1503	1504	.

O	1505	1508	The
O	1509	1519	randomized
O	1520	1526	groups
O	1527	1531	were
O	1532	1542	comparable
O	1543	1546	for
O	1547	1550	age
O	1551	1552	(
B-age	1552	1554	51
I-age	1554	1555	.
I-age	1555	1556	8
I-age	1557	1562	years
O	1562	1563	)
O	1563	1564	,
O	1565	1575	proportion
O	1576	1578	of
O	1579	1581	ER
O	1581	1582	-
O	1582	1590	negative
O	1591	1597	tumors
O	1598	1599	(
O	1599	1601	22
O	1601	1602	%
O	1602	1603	)
O	1603	1604	,
O	1605	1613	axillary
O	1614	1618	node
O	1619	1629	metastasis
O	1630	1631	(
O	1631	1633	42
O	1633	1634	%
O	1634	1635	)
O	1635	1636	,
O	1637	1649	reproductive
O	1650	1659	variables
O	1659	1660	,
O	1661	1668	tobacco
O	1669	1676	smoking
O	1676	1677	,
O	1678	1683	blood
O	1684	1692	pressure
O	1692	1693	,
O	1694	1708	anthropometric
O	1709	1721	measurements
O	1722	1725	and
O	1726	1734	hormonal
O	1735	1738	and
O	1739	1748	metabolic
O	1749	1759	parameters
O	1759	1760	.

O	1761	1766	DIANA
O	1766	1767	-
O	1767	1768	5
O	1769	1772	has
O	1773	1776	the
O	1777	1786	potential
O	1787	1789	to
O	1790	1799	establish
O	1800	1807	whether
O	1808	1809	a
O	1810	1823	Mediterranean
O	1823	1824	-
O	1824	1835	macrobiotic
O	1836	1845	lifestyle
O	1846	1849	may
B-outcome	1850	1856	reduce
I-outcome	1857	1863	breast
I-outcome	1864	1870	cancer
I-outcome	1871	1882	recurrences
O	1882	1883	.

O	1884	1886	We
O	1887	1891	will
O	1892	1898	assess
O	1899	1907	evidence
O	1908	1910	of
O	1911	1924	effectiveness
O	1924	1925	,
O	1926	1931	first
O	1932	1934	by
O	1935	1944	comparing
O	1945	1948	the
O	1949	1958	incidence
O	1959	1961	of
O	1962	1972	additional
O	1973	1979	breast
O	1980	1986	cancer
O	1987	1993	events
O	1994	1995	(
O	1995	2000	local
O	2001	2003	or
O	2004	2011	distant
O	2012	2022	recurrence
O	2022	2023	,
O	2024	2030	second
O	2031	2042	ipsilateral
O	2043	2045	or
O	2046	2059	contralateral
O	2060	2066	cancer
O	2066	2067	)
O	2068	2070	in
O	2071	2074	the
O	2075	2087	intervention
O	2088	2091	and
O	2092	2094	in
O	2095	2098	the
O	2099	2106	control
O	2107	2112	group
O	2112	2113	,
O	2114	2116	by
O	2117	2119	an
O	2120	2129	intention
O	2129	2130	-
O	2130	2132	to
O	2132	2133	-
O	2133	2138	treat
O	2139	2147	analysis
O	2147	2148	,
O	2149	2152	and
O	2153	2159	second
O	2160	2162	by
O	2163	2172	analyzing
O	2173	2176	the
O	2177	2186	incidence
O	2187	2189	of
O	2190	2196	breast
O	2197	2203	cancer
O	2204	2210	events
O	2211	2213	in
O	2214	2217	the
O	2218	2223	total
O	2224	2229	study
O	2230	2240	population
O	2241	2243	by
O	2244	2254	compliance
O	2255	2265	assessment
O	2266	2271	score
O	2271	2272	.
